Evidence map›Paper›PMID 36962496›Full record

ArticlePLOS global public health2022

Incentivizing optimal risk map use for Triatoma infestans surveillance in urban environments.

Claudia Arevalo-Nieto, Justin Sheen, Gian Franco Condori-Luna, Carlos Condori-Pino, Julianna Shinnick, Jennifer K Peterson, Ricardo Castillo-Neyra, Michael Z Levy

Open access · goldFull text read
In one paragraph

Article in PLOS global public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Claudia Arevalo-NietoZoonotic Disease Research Laboratory, One Health Unit, School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Arequipa, Perú.
Justin SheenDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Gian Franco Condori-LunaZoonotic Disease Research Laboratory, One Health Unit, School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Arequipa, Perú.
Carlos Condori-PinoZoonotic Disease Research Laboratory, One Health Unit, School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Arequipa, Perú.
Julianna ShinnickDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Jennifer K PetersonDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Ricardo Castillo-NeyraDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Michael Z LevyDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.ORCID https://orcid.org/0000-0002-4661-3764
University of Pennsylvania · USUniversidad Peruana Cayetano Heredia · PE

Funding

An immune system for the city: a new paradigm for control of urban disease vectorsR01AI146129 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI LEVY, MICHAEL Z, PAZ-SOLDAN, VALERIE ANDREA · 2019 to 2023
$3.3M
Disrupting Vector-borne Disease Transmission in Complex Urban EnvironmentsR01AI101229 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI LEVY, MICHAEL Z · 2013 to 2017
$3.1M
Control and Prevention of Zoonotic Epidemics in Cities: A Socio-Spatial ApproachK01AI139284 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI CASTILLO NEYRA, RICARDO · 2019 to 2023
$710k
NIAID NIH HHS K01 AI139284NIAID NIH HHS R01 AI101229NIAID NIH HHS R01 AI146129
6 · The paper itself

Abstract

In Arequipa, Peru, a large-scale vector control campaign has successfully reduced urban infestations of the Chagas disease vector, Triatoma infestans. In addition to preventing new infections with Trypanosoma cruzi (etiological agent of Chagas disease), the campaign produced a wealth of information about the distribution and density of vector infestations. We used these data to create vector infestation risk maps for the city in order to target the last few remaining infestations, which are unevenly distributed and difficult to pinpoint. Our maps, which are provided on a mobile app, display color-coded, individual house-level estimates of T. infestans infestation risk. Entomologic surveillance personnel can use the maps to select homes to inspect based on estimated risk of infestation, as well as keep track of which parts of a given neighborhood they have inspected to ensure even surveillance throughout the zone. However, the question then becomes, how do we encourage surveillance personnel to actually use these two functionalities of the risk map? As such, we carried out a series of rolling trials to test different incentive schemes designed to encourage the following two behaviors by entomologic surveillance personnel in Arequipa: (i) preferential inspections of homes shown as high risk on the maps, and (ii) even surveillance across the geographical distribution of a given area, which we term, 'spatial coverage.' These two behaviors together constituted what we termed, 'optimal map use.' We found that several incentives resulted in one of the two target behaviors, but just one incentive scheme based on the game of poker resulted in optimal map use. This poker-based incentive structure may be well-suited to improve entomological surveillance activities and other complex multi-objective tasks.

Identifiers

PMID36962496
PMCPMC10021448
OpenAlexW4289637475

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read24
identifiers read12
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.